相关实验视频

Updated: Sep 26, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

基于淋巴细胞的DNA工程同源向人造抗原呈现细胞用于个性化癌症免疫疗法

Lele Sun¹, Fengyun Shen¹, Zijian Xiong¹

¹Institute of Functional Nano & Soft Materials (FUNSOM) Jiangsu Key Lab Carbon Based Functional Materials and Devices, Soochow University, Suzhou 215123, Jiangsu, China.

Journal of the American Chemical Society

|April 19, 2022

概括

研究人员使用非侵入性细胞表面工程开发了基于淋巴细胞的新型人造抗原呈现细胞 (aAPC). 这些被设计的aAPC在体内有效地激活T细胞,为先进的瘤免疫治疗策略显示出希望.

科学领域:

免疫学
生物技术
癌症学

背景情况:

人工抗原呈现细胞 (aAPC) 对于瘤免疫疗法至关重要,但为了有效的体内T细胞激活,它们很难模仿自然的APC.
开发能够复制自然APC功能的aAPC,包括定位和特定的T细胞激活,仍然是一个重大挑战.

研究的目的:

使用非侵入性活细胞表面工程设计基于淋巴细胞的新型人造抗原呈现细胞 (LC-aAPC).
为了实现T细胞激活配体的自然模拟APC,以优化体内T细胞激活.
评估LC-aAPC与免疫检查点抑制剂结合用于瘤免疫治疗的治疗潜力.

主要方法:

通过通过脂质DNA介导的非侵入性活细胞表面工程将T细胞激活配体集成到自然淋巴细胞上来构建LC-aAPC.
采用自下自上自组合方法,以实现对LC-aAPC的特定分布.
在体内评估LC-aAPC的定位能力和T细胞激活潜力.

主要成果:

成功设计的LC-aAPC具有模仿自然APC的T细胞激活配体分布.
证明脂质-DNA工程方法保留了淋巴细胞指导受体功能,使其能够迁移到淋巴器官.
显示LC-aAPCs在体内有效激活抗原特异性T细胞,并与免疫检查点抑制剂结合时显著抑制瘤生长.

结论:

这项研究提出了基于自然淋巴细胞的人工抗原呈现细胞 (LC-aAPC) 的新设计,用于体内瘤免疫治疗.
脂质DNA介导的非侵入性活细胞表面工程是开发先进的基于细胞的治疗方法的强大工具.
开发的LC-aAPC为增强抗原特异性T细胞反应和改善瘤治疗结果提供了有希望的策略.

更多相关视频

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...